Literature DB >> 24686434

Aspects on gallbladder cancer in 2014.

Ake Åndrén-Sandberg1, Yang Deng.   

Abstract

PURPOSE OF REVIEW: To discuss some key issues involved in the management of gallbladder cancer (GBC). RECENT
FINDINGS: The decline in incidence and mortality of GBC began decades before the introduction of laparoscopic surgery. In consecutive autopsies and in cases in which cholelithiasis was present, the incidence of gallbladder carcinoma is 3-4%. A number of genetic alterations have been identified in the different stages of GBC and they support the morphological evidence of two pathways by which tumors develop. Some of these genetic changes are associated with particular risk factors. All management of GBC and all comparisons of treatment results from different centers must be based on the stages.
SUMMARY: Simple cholecystectomy is the adequate treatment for T1a GBC. Lymph node excision improved survival in patients with T2 lesions. Radical en bloc resection of T2 tumors offers greater benefit over conventional cholecystectomy alone in terms of greater long-term survival times. Provided that negative surgical margins are secured, hepatectomy and lymph node resection can, therefore, be withheld in most cases in the surgical treatment of pT2 GBC. With improvements in surgical and anesthetic techniques, aggressive surgery has proven to be performed with safety.

Entities:  

Mesh:

Year:  2014        PMID: 24686434     DOI: 10.1097/MOG.0000000000000068

Source DB:  PubMed          Journal:  Curr Opin Gastroenterol        ISSN: 0267-1379            Impact factor:   3.287


  9 in total

1.  Novel strategy for laparoscopic treatment of pT2 gallbladder carcinoma.

Authors:  Osamu Itano; Go Oshima; Takuya Minagawa; Masahiro Shinoda; Minoru Kitago; Yuta Abe; Taizo Hibi; Hiroshi Yagi; Naruhiko Ikoma; Satoshi Aiko; Miho Kawaida; Yohei Masugi; Kaori Kameyama; Michiie Sakamoto; Yuko Kitagawa
Journal:  Surg Endosc       Date:  2015-03-05       Impact factor: 4.584

Review 2.  Gallbladder carcinoma: Prognostic factors and therapeutic options.

Authors:  Thorsten Oliver Goetze
Journal:  World J Gastroenterol       Date:  2015-11-21       Impact factor: 5.742

Review 3.  Gallbladder Cancer in the 21st Century.

Authors:  Rani Kanthan; Jenna-Lynn Senger; Shahid Ahmed; Selliah Chandra Kanthan
Journal:  J Oncol       Date:  2015-09-01       Impact factor: 4.375

4.  Clinical correlation of calpain-1 and glypican-3 expression with gallbladder carcinoma.

Authors:  Weiqing Luo; Zhigang Ren; Sheng Gao; Hailong Jin; Geer Zhang; Lin Zhou; Shusen Zheng
Journal:  Oncol Lett       Date:  2016-01-07       Impact factor: 2.967

5.  Long-Term Outcomes and Prognostic Factors in Advanced Gallbladder Cancer: Focus on the Advanced T Stage.

Authors:  Chen Chen; Zhimin Geng; Haoxin Shen; Huwei Song; Yaling Zhao; Guanjun Zhang; Wenzhi Li; Li Ma; Lin Wang
Journal:  PLoS One       Date:  2016-11-15       Impact factor: 3.240

6.  BRD4 inhibitor and histone deacetylase inhibitor synergistically inhibit the proliferation of gallbladder cancer in vitro and in vivo.

Authors:  Shilei Liu; Fengnan Li; Lijia Pan; Ziyi Yang; Yijun Shu; Wenjie Lv; Ping Dong; Wei Gong
Journal:  Cancer Sci       Date:  2019-07-11       Impact factor: 6.716

Review 7.  Neoadjuvant Chemotherapy for Advanced Gallbladder Cancer: Do We have Enough Evidence? A Systematic Review.

Authors:  Shah Naveed; Hasina Qari; Cao M Thau; Pipit Burasakarn; Abdul W Mir
Journal:  Euroasian J Hepatogastroenterol       Date:  2021 Jul-Dec

8.  Histone Deacetylase Inhibitors Inhibit the Proliferation of Gallbladder Carcinoma Cells by Suppressing AKT/mTOR Signaling.

Authors:  Peng Zhang; Zhiyong Guo; Ying Wu; Ronglin Hu; Jun Du; Xiaoshun He; Xingyuan Jiao; Xiaofeng Zhu
Journal:  PLoS One       Date:  2015-08-19       Impact factor: 3.240

9.  Up-regulation of PKM2 promote malignancy and related to adverse prognostic risk factor in human gallbladder cancer.

Authors:  Wei Lu; Yang Cao; Yijian Zhang; Sheng Li; Jian Gao; Xu-An Wang; Jiasheng Mu; Yun-Ping Hu; Lin Jiang; Ping Dong; Wei Gong; Yingbin Liu
Journal:  Sci Rep       Date:  2016-06-10       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.